Colorectal Neoplasia in CDH1 Pathogenic Variant Carriers: A Multicenter Analysis

Peter P. Stanich*, Dareen Elgindi, Elena Stoffel, Erika Koeppe, Ajay Bansal, Rachel Stetson, Debra L. Collins, Dana Farengo Clark, Eve Karloski, Beth Dudley, Randall E. Brand, Michael J. Hall, Yana Chertock, Brian A. Sullivan, Charles Muller, Alice Hinton, Bryson W. Katona, Sonia S. Kupfer

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

2 Scopus citations

Abstract

INTRODUCTION:Germline variants in CDH1 are associated with elevated risks of diffuse gastric cancer and lobular breast cancer. It is uncertain whether there is an increased risk of colorectal neoplasia.METHODS:This was a retrospective analysis of colonoscopy outcomes in patients with germline CDH1 pathogenic/likely pathogenic variants.RESULTS:Eighty-five patients were included with a mean age of 46.9 years. Initial colonoscopy found adenomatous polyps in 30 patients (35.3%), including advanced adenomas in 9 (10.6%). No colorectal cancers were identified on index or subsequent colonoscopies (when available).DISCUSSION:CDH1 carriers have colorectal neoplasia identified at similar rates as in the general population. Despite potential difficulties after gastrectomy, colorectal cancer screening remains important in this population.

Original languageEnglish (US)
Pages (from-to)1877-1879
Number of pages3
JournalAmerican Journal of Gastroenterology
Volume117
Issue number11
DOIs
StatePublished - Nov 1 2022

Funding

Potential competing interests: P.P.S. receives research support from Emtora Biosciences, Janssen Pharmaceuticals, Pfizer, and the PTEN Research Foundation. B.A.S. receives support from Exact Sciences. B.W.K. receives research support from Epigenomics, Freenome, Guardant Health, Immunovia, and Janssen Pharmaceuticals and has consulted for Exact Sciences. S.S.K. receives research support from Immunovia and Invitae. No other authors have any potential conflicts to disclose. Financial support: This study was supported by the Ohio State University Center for Clinical and Translational Science grant (National Center for Advancing Translational Sciences, Grant UL1TR002733). B.A.S. is supported by the AGA Research Foundation’s AGA Research Scholar Award—AGA2021-13-03. A.B. is supported by the NIH/NCI Cancer Center Support Grant P30 CA168524 to the University of Kansas Cancer Center.

ASJC Scopus subject areas

  • Gastroenterology
  • Hepatology

Fingerprint

Dive into the research topics of 'Colorectal Neoplasia in CDH1 Pathogenic Variant Carriers: A Multicenter Analysis'. Together they form a unique fingerprint.

Cite this